What is Axsome Therapeutics?
Axsome Therapeutics is a biopharmaceutical company focused on cns disorders company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Biopharmaceutical company focused on CNS disorders
- Headquarters
- New York, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: AXSM
What is Axsome Therapeutics?
Axsome Therapeutics is a biopharmaceutical company focused on cns disorders company headquartered in New York, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Axsome Therapeutics is a biopharmaceutical company focused on cns disorders company headquartered in New York, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Axsome Therapeutics should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Axsome Therapeutics offer?
Axsome Therapeutics's profile centers on CNS medicines, Depression treatment, Migraine pipeline, Sleep disorders.
- CNS medicines· Biopharmaceutical company focused on CNS disorders
- Depression treatment· Biopharmaceutical company focused on CNS disorders
- Migraine pipeline· Biopharmaceutical company focused on CNS disorders
- Sleep disorders· Biopharmaceutical company focused on CNS disorders
- Clinical development· Biopharmaceutical company focused on CNS disorders
- Commercialization· Biopharmaceutical company focused on CNS disorders
How does Axsome Therapeutics make money?
Axsome Therapeutics makes money through commercial activity tied to biopharmaceutical company focused on cns disorders.
Axsome Therapeutics monetizes through the model common to biopharmaceutical company focused on cns disorders: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Axsome Therapeutics?
Axsome Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Axsome Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Axsome Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Axsome Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Axsome Therapeutics's leadership?
Axsome Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.axsome.com- Axsome Therapeutics investor relationsInvestor relations / corporate contactcontact via https://www.axsome.com
- Axsome Therapeutics media relationsMedia or communications contact routecontact via https://www.axsome.com
How is Axsome Therapeutics funded?
Axsome Therapeutics's current status is Public company; Nasdaq: AXSM.
Axsome Therapeutics's capital profile is best understood through its current public-company status: Public company; Nasdaq: AXSM. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Axsome Therapeutics get here?
Axsome Therapeutics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingAxsome Therapeutics is foundedThe company begins building in biopharmaceutical company focused on cns disorders.
- Scale-upCommercial footprint expandsAxsome Therapeutics broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: AXSMPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Axsome Therapeutics's competitors?
Axsome Therapeutics competes with larger incumbents and focused specialists in biopharmaceutical company focused on cns disorders.
Axsome Therapeutics — frequently asked questions
